<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Arch Biopartners Inc — News on 6ix</title>
<link>https://6ix.com/company/arch-biopartners-inc</link>
<description>Latest news and press releases for Arch Biopartners Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 30 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/arch-biopartners-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835f1d578dffbe2df12daa3.webp</url>
<title>Arch Biopartners Inc</title>
<link>https://6ix.com/company/arch-biopartners-inc</link>
</image>
<item>
<title>Royal Columbian Hospital begins patient recruitment in Arch Biopartners' Phase II trial of LSALT peptide targeting CS-AKI</title>
<link>https://6ix.com/company/arch-biopartners-inc/news/royal-columbian-hospital-begins-patient-recruitment-in-arch-biopartners-phase-ii-trial-of-lsalt-peptide-targeting-cs-aki</link>
<guid isPermaLink="true">https://6ix.com/company/arch-biopartners-inc/news/royal-columbian-hospital-begins-patient-recruitment-in-arch-biopartners-phase-ii-trial-of-lsalt-peptide-targeting-cs-aki</guid>
<pubDate>Thu, 30 Apr 2026 11:00:00 GMT</pubDate>
<description>TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (&#x201C;Arch&#x201D; or the ...</description>
</item>
<item>
<title>Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial</title>
<link>https://6ix.com/company/arch-biopartners-inc/news/arch-biopartners-and-the-fraser-health-authority-enter-into-a-clinical-trial-agreement-for-the-phase-ii-cardiac-surgery-associated-aki-trial</link>
<guid isPermaLink="true">https://6ix.com/company/arch-biopartners-inc/news/arch-biopartners-and-the-fraser-health-authority-enter-into-a-clinical-trial-agreement-for-the-phase-ii-cardiac-surgery-associated-aki-trial</guid>
<pubDate>Tue, 24 Mar 2026 13:13:43 GMT</pubDate>
<description>TORONTO, March 24, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (&#x201C;Arch&#x201D; or the ...</description>
</item>
<item>
<title>Arch Biopartners Announces St. Michael's Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide</title>
<link>https://6ix.com/company/arch-biopartners-inc/news/arch-biopartners-announces-st-michaels-hospital-commences-patient-dosing-in-the-phase-ii-cs-aki-trial-of-lsalt-peptide</link>
<guid isPermaLink="true">https://6ix.com/company/arch-biopartners-inc/news/arch-biopartners-announces-st-michaels-hospital-commences-patient-dosing-in-the-phase-ii-cs-aki-trial-of-lsalt-peptide</guid>
<pubDate>Fri, 20 Mar 2026 11:05:00 GMT</pubDate>
<description>TORONTO, March 20, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (&#x201C;Arch&#x201D; or the ...</description>
</item>
<item>
<title>Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease</title>
<link>https://6ix.com/company/arch-biopartners-inc/news/arch-biopartners-scientists-publish-data-122800449</link>
<guid isPermaLink="true">https://6ix.com/company/arch-biopartners-inc/news/arch-biopartners-scientists-publish-data-122800449</guid>
<pubDate>Mon, 09 Feb 2026 12:28:00 GMT</pubDate>
<description>TORONTO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced that a scientific team led by Dr. Justin Chun at the University of Calgary has published new data in the peer-reviewed journal Inflammation Research identifying interleukin-32 (IL-32) as a novel lipid droplet-associated cytokine that may contribute to tubular injury and inflammation in diabetic kidney disease (DKD). The newly published findings, based on</description>
</item>
<item>
<title>Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board</title>
<link>https://6ix.com/company/arch-biopartners-inc/news/arch-biopartners-announces-appointment-dr-131500179</link>
<guid isPermaLink="true">https://6ix.com/company/arch-biopartners-inc/news/arch-biopartners-announces-appointment-dr-131500179</guid>
<pubDate>Fri, 16 Jan 2026 13:15:00 GMT</pubDate>
<description>TORONTO, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today the appointment of Dr. Patrick Vink as Chairman of the Company’s Board of Directors, effective January 15, 2026. Dr. Vink, M.D., M.B.A., has been an advisor to the pharmaceutical industry since 2015 and has served as a non-executive board member or chair of several public and private companies in North America and Europe. He has overseen or supported sev</description>
</item>
<item>
<title>Arch Biopartners Announces Ethics Approval for St. Michael's Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide</title>
<link>https://6ix.com/company/arch-biopartners-inc/news/arch-biopartners-announces-ethics-approval-for-st-michaels-hospital-to-participate-in-the-phase-ii-cardiac-surgery-associated-aki-trial-for-lsalt-peptide</link>
<guid isPermaLink="true">https://6ix.com/company/arch-biopartners-inc/news/arch-biopartners-announces-ethics-approval-for-st-michaels-hospital-to-participate-in-the-phase-ii-cardiac-surgery-associated-aki-trial-for-lsalt-peptide</guid>
<pubDate>Tue, 16 Dec 2025 12:40:00 GMT</pubDate>
<description>TORONTO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (&#x201C;Arch&#x201D; or th...</description>
</item>
<item>
<title>Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide</title>
<link>https://6ix.com/company/arch-biopartners-inc/news/arch-biopartners-announces-ethics-approval-124000834</link>
<guid isPermaLink="true">https://6ix.com/company/arch-biopartners-inc/news/arch-biopartners-announces-ethics-approval-124000834</guid>
<pubDate>Tue, 16 Dec 2025 12:40:00 GMT</pubDate>
<description>TORONTO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the University Health Network Research Ethics Board (“UHN REB”) has granted ethics approval for St. Michael’s Hospital, a site of Unity Health Toronto, to participate in Arch’s ongoing Phase II trial evaluating LSALT peptide for the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). With the UHN REB approval, issued</description>
</item>
<item>
<title>Arch Biopartners Closes Non-Brokered Private Placement</title>
<link>https://6ix.com/company/arch-biopartners-inc/news/arch-biopartners-closes-non-brokered-private-placement</link>
<guid isPermaLink="true">https://6ix.com/company/arch-biopartners-inc/news/arch-biopartners-closes-non-brokered-private-placement</guid>
<pubDate>Wed, 19 Nov 2025 21:27:50 GMT</pubDate>
<description>TORONTO, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc ., (&#x201C;Arch&#x201D; or t...</description>
</item>
<item>
<title>Arch Biopartners Arranges Non-Brokered Private Placement</title>
<link>https://6ix.com/company/arch-biopartners-inc/news/arch-biopartners-arranges-non-brokered-private-placement</link>
<guid isPermaLink="true">https://6ix.com/company/arch-biopartners-inc/news/arch-biopartners-arranges-non-brokered-private-placement</guid>
<pubDate>Mon, 10 Nov 2025 13:10:00 GMT</pubDate>
<description>TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc ., (&#x201C;Arch&#x201D; ...</description>
</item>
<item>
<title>Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia</title>
<link>https://6ix.com/company/arch-biopartners-inc/news/arch-biopartners-expands-phase-ii-cardiac-surgery-associated-aki-trial-to-include-royal-columbian-hospital-in-british-columbia</link>
<guid isPermaLink="true">https://6ix.com/company/arch-biopartners-inc/news/arch-biopartners-expands-phase-ii-cardiac-surgery-associated-aki-trial-to-include-royal-columbian-hospital-in-british-columbia</guid>
<pubDate>Wed, 05 Nov 2025 13:30:00 GMT</pubDate>
<description>TORONTO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (&#x201C;Arch&#x201D; or th...</description>
</item>
<item>
<title>Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD)</title>
<link>https://6ix.com/company/arch-biopartners-inc/news/arch-strengthens-its-position-as-a-leading-kidney-therapeutics-company-with-the-acquisition-of-a-breakthrough-platform-to-develop-new-drugs-targeting-chronic-kidney-disease-ckd</link>
<guid isPermaLink="true">https://6ix.com/company/arch-biopartners-inc/news/arch-strengthens-its-position-as-a-leading-kidney-therapeutics-company-with-the-acquisition-of-a-breakthrough-platform-to-develop-new-drugs-targeting-chronic-kidney-disease-ckd</guid>
<pubDate>Wed, 17 Sep 2025 11:15:00 GMT</pubDate>
<description>Arch acquires a new CKD platform that has the potential to produce next-generation CKD drugs for ...</description>
</item>
<item>
<title>Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury</title>
<link>https://6ix.com/company/arch-biopartners-inc/news/arch-biopartners-announces-first-patient-successfully-dosed-at-toronto-general-hospital-in-phase-ii-trial-of-lsalt-peptide-targeting-cardiac-surgery-associated-acute-kidney-injury</link>
<guid isPermaLink="true">https://6ix.com/company/arch-biopartners-inc/news/arch-biopartners-announces-first-patient-successfully-dosed-at-toronto-general-hospital-in-phase-ii-trial-of-lsalt-peptide-targeting-cardiac-surgery-associated-acute-kidney-injury</guid>
<pubDate>Wed, 06 Aug 2025 11:25:00 GMT</pubDate>
<description>First patient successfully completes dosing at Toronto General Hospital St. Michael&#x2019;s ...</description>
</item>
<item>
<title>Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI)</title>
<link>https://6ix.com/company/arch-biopartners-inc/news/arch-biopartners-announces-start-of-patient-recruitment-in-phase-ii-pontiak-trial-targeting-drug-toxin-related-acute-kidney-injury-aki</link>
<guid isPermaLink="true">https://6ix.com/company/arch-biopartners-inc/news/arch-biopartners-announces-start-of-patient-recruitment-in-phase-ii-pontiak-trial-targeting-drug-toxin-related-acute-kidney-injury-aki</guid>
<pubDate>Tue, 22 Jul 2025 11:30:00 GMT</pubDate>
<description>TORONTO, July 22, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (&#x201C;Arch&#x201D; or the...</description>
</item>
<item>
<title>Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)</title>
<link>https://6ix.com/company/arch-biopartners-inc/news/arch-biopartners-announces-toronto-general-hospital-ethics-board-approval-to-join-the-phase-ii-trial-for-lsalt-peptide-targeting-cardiac-surgery-associated-acute-kidney-injury-cs-aki</link>
<guid isPermaLink="true">https://6ix.com/company/arch-biopartners-inc/news/arch-biopartners-announces-toronto-general-hospital-ethics-board-approval-to-join-the-phase-ii-trial-for-lsalt-peptide-targeting-cardiac-surgery-associated-acute-kidney-injury-cs-aki</guid>
<pubDate>Tue, 22 Apr 2025 10:55:00 GMT</pubDate>
<description>TORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (&#x201C;Arch&#x201D; or ...</description>
</item>
<item>
<title>Arch Biopartners Announces Health Canada No Objection Letter (NOL) Granted for Investigator-Led Phase II PONTiAK Trial Using Cilastatin to Target Drug-Toxin-Related Acute Kidney Injury (AKI)</title>
<link>https://6ix.com/company/arch-biopartners-inc/news/arch-biopartners-announces-health-canada-no-objection-letter-nol-granted-for-investigator-led-phase-ii-pontiak-trial-using-cilastatin-to-target-drug-toxin-related-acute-kidney-injury-aki</link>
<guid isPermaLink="true">https://6ix.com/company/arch-biopartners-inc/news/arch-biopartners-announces-health-canada-no-objection-letter-nol-granted-for-investigator-led-phase-ii-pontiak-trial-using-cilastatin-to-target-drug-toxin-related-acute-kidney-injury-aki</guid>
<pubDate>Tue, 18 Feb 2025 12:05:00 GMT</pubDate>
<description>TORONTO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (&#x201C;Arch&#x201D; or t...</description>
</item>
<item>
<title>InvestmentPitch Media Video Discusses Arch Biopartners' Awarding of $6.7 Million from Canadian Government's Strategic Innovation Fund - Video Available on Investmentpitch.com</title>
<link>https://6ix.com/company/arch-biopartners-inc/news/investmentpitch-media-video-discusses-arch-biopartners-awarding-of-dollar67-million-from-canadian-governments-strategic-innovation-fund-video-available-on-investmentpitchcom</link>
<guid isPermaLink="true">https://6ix.com/company/arch-biopartners-inc/news/investmentpitch-media-video-discusses-arch-biopartners-awarding-of-dollar67-million-from-canadian-governments-strategic-innovation-fund-video-available-on-investmentpitchcom</guid>
<pubDate>Thu, 17 Dec 2020 14:15:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - December 17, 2020) - Arch Biopartners (TSXV: AR...</description>
</item>
<item>
<title>IIROC Trading Resumption - ARCH</title>
<link>https://6ix.com/company/arch-biopartners-inc/news/iiroc-trading-resumption-arch</link>
<guid isPermaLink="true">https://6ix.com/company/arch-biopartners-inc/news/iiroc-trading-resumption-arch</guid>
<pubDate>Tue, 15 Dec 2020 18:05:00 GMT</pubDate>
<description>IIROC Trading Resumption - ARCH VANCOUVER, BC , Dec. 15, 2020 /CNW/ - T...</description>
</item>
<item>
<title>IIROC Trading Halt - ARCH</title>
<link>https://6ix.com/company/arch-biopartners-inc/news/iiroc-trading-halt-arch</link>
<guid isPermaLink="true">https://6ix.com/company/arch-biopartners-inc/news/iiroc-trading-halt-arch</guid>
<pubDate>Tue, 15 Dec 2020 16:35:00 GMT</pubDate>
<description>IIROC Trading Halt - ARCH VANCOUVER, BC , Dec. 15, 2020 /CNW/ - The fol...</description>
</item>
<item>
<title>Arch Biopartners Announces Completion of GMP Manufacturing of Metablok Vials</title>
<link>https://6ix.com/company/arch-biopartners-inc/news/arch-biopartners-announces-completion-of-gmp-manufacturing-of-metablok-vials</link>
<guid isPermaLink="true">https://6ix.com/company/arch-biopartners-inc/news/arch-biopartners-announces-completion-of-gmp-manufacturing-of-metablok-vials</guid>
<pubDate>Wed, 26 Sep 2018 13:29:00 GMT</pubDate>
<description>Arch Biopartners Announces Completion of GMP Manufacturing of Metablok Vials Canad...</description>
</item>
<item>
<title>Arch Biopartners Engages Dalton Pharma Services for GMP Manufacturing of Metablok</title>
<link>https://6ix.com/company/arch-biopartners-inc/news/arch-biopartners-engages-dalton-pharma-services-for-gmp-manufacturing-of-metablok</link>
<guid isPermaLink="true">https://6ix.com/company/arch-biopartners-inc/news/arch-biopartners-engages-dalton-pharma-services-for-gmp-manufacturing-of-metablok</guid>
<pubDate>Tue, 14 Aug 2018 13:23:00 GMT</pubDate>
<description>Arch Biopartners Engages Dalton Pharma Services for GMP Manufacturing of Metablok ...</description>
</item>
</channel>
</rss>